Eosinophil-Derived Neurotoxin and Respiratory Tract Infection and Inflammation: Implications for COVID-19 Management.

The current pandemic of COVID-19 and the identification of accessible biomarkers of disease progression is of clinical importance in the management of this novel and serious disease. This study was completed to provide information regarding 1 possible uniquely upregulated marker in this illness, eosinophil-derived neurotoxin (EDN-1). A literature search was undertaken to provide medical data regarding EDN-1 as a biomarker in the clinical setting. The literature identified was further analyzed to identify its use in the clinical setting of viral disease and asthma.